Green Cross Corporation
South Korean maker of plasma-derived immunoglobulins and vaccines, selling at home and now in the US.
On the record
Checkpoint: Two-dose varicella vaccine Phase 3 Korea trial progress toward targeted approval
The call
A profitable, decades-old plasma and vaccine business in Korea is betting its growth on Alyglo taking US share from CSL and Grifols, with mixed early results.
Green Cross makes blood plasma treatments and vaccines, mostly sold in South Korea where it has strong government contracts and FDA approvals that are hard for others to replicate quickly. But the company is betting on two new US products (Alyglo for immune deficiency, and a chickenpox vaccine to compete with Merck's Varivax) to drive growth, and investors doubt these will work because the company spends less on research than rivals like CSL and Grifols, and has few backup products in development. The stock has dropped 18% because Wall Street wants to see Alyglo actually sell well in America by early 2026 and the chickenpox vaccine show real promise in tests; if those happen, the company could prove critics wrong, but without them the stock will likely stay stuck in place even though the core business in Korea stays solid.
Why
01
AI pressure: None apparent. Plasma collection and vaccine manufacturing depend on physical supply chains and regulatory approvals, not something AI models replace. Could AI do the core job? Unlikely.
02
Bigger players: CSL Behring and Grifols in immunoglobulins, Merck in varicella vaccines. CSL and Grifols already sell established immunoglobulin products in the US market that Alyglo must take share from to grow. Could a giant copy it? Probably.
03
What protects it. Plasma-collection infrastructure, FDA approval for Alyglo, and Korean government vaccine contracts that outside players can't easily replicate.
What would change this call
Q1 2026 Alyglo US sales report shows whether +~300% YoY growth materialized. Confirms or refutes GC's ability to take US share from CSL Behring and Grifols.
Korea leg of two-dose varicella Phase 3 trial results versus Merck's Varivax. Shows whether GC's vaccine can credibly compete with Merck's incumbent product.
H2 2026 earnings versus IBK's reduced 190k won target and 2.035T won guidance. Indicates whether the pipeline-gap concerns behind the 18% stock drop are easing or worsening.
Korea leg of two-dose varicella Phase 3 trial results versus Merck's Varivax. Shows whether GC's vaccine can credibly compete with Merck's incumbent product.
H2 2026 earnings versus IBK's reduced 190k won target and 2.035T won guidance. Indicates whether the pipeline-gap concerns behind the 18% stock drop are easing or worsening.
Key numbers
- Q1 2026 US Alyglo sales projected +300% YoY
- 2026 revenue guidance 2.035T won, +0.6% YoY
- Q2 2026 operating profit down 89.4% YoY
Named risks
- Post-Alyglo pipeline gap driving investor skepticism, reflected in 18% stock drop May to June 2026.
- Modest R&D spend (8.6% of revenue in 2025) versus domestic peers investing in large AI-discovery deals.
- Alyglo and varicella growth bets face entrenched global incumbents (CSL, Grifols, Takeda, Merck) with no structural US edge.
- Q2 2026 operating profit fell 89.4% YoY due to delayed influenza vaccine bulk sales, showing earnings volatility.
- Founding-family (Huh) governance control raises related-party deal risk, as seen in GC WellBeing stake sale to parent.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| CSL Behring, Grifols, Takeda | contesting | Alyglo US launch Sept 2024 fights entrenched IVIG incumbents; ~300% YoY US growth projected Q1 2026 |
| Merck (Varivax) | contesting | Two-dose varicella Phase 3 trials began July 2026, targeting 2028 approval as direct comparator |
| SK Biopharmaceuticals | losing to | SK signed $2.5B AI drug-discovery deal with Insilico Medicine June 2026, dwarfing GC's AI moves |
| Hanmi Pharmaceutical | losing to | Nature (July 2026) ranked Hanmi and SK Biopharm as 'Innovation Leaders' vs GC as 'Emerging Innovator' |
| Eli Lilly | contesting | Sold Curevo vaccine unit to Lilly for $303.92M in May 2026, exiting rather than competing in that niche |
Questions people ask
- Is Green Cross Corporation (GC Biopharma) profitable in 2026?
- Yes. 2026 full-year guidance from IBK Investment & Securities (July 21, 2026) projects operating profit of 75.3 billion won, up 9.0% YoY, on revenue of 2.035 trillion won, though Q2 2026 operating profit fell 89.4% YoY due to delayed flu vaccine bulk sales.
- Could AI replace GC Biopharma's drug discovery work?
- Not the core business. GC's moat is plasma-collection infrastructure, FDA/WHO approvals, and Korean immunization contracts, all physical and regulatory, not AI-exposed. AI is used narrowly in early antibody discovery via an April 2026 Galux partnership and a May 2026 government AI drug-discovery project, not production.
- Who is GC Biopharma's biggest competitor in the US market?
- In IVIG immunoglobulins, incumbents CSL Behring, Grifols, and Takeda dominate the market GC's Alyglo (FDA-approved December 15, 2023, US launch September 2024) is trying to enter. In varicella vaccines, Merck's Varivax is the direct comparator in GC's ongoing Phase 3 trials as of July 2026.
- Why did GC Biopharma's stock price drop in 2026?
- Shares fell about 18%, from 150,200 won on May 27, 2026 to 126,400 won on June 12, 2026, after GC Biopharma announced the sale of its US vaccine subsidiary Curevo to Eli Lilly, sparking investor concern over a 'post-Alyglo' pipeline gap.
- Who owns GC Biopharma?
- GC Biopharma (KRX: 006280) is a subsidiary of holding company GC Corp (formerly Green Cross Holdings, KRX: 005250), controlled by the founding Huh family, with CEO Il-Sub Huh also serving as Chairman of GC Corp, as of 2026.
- Did GC Biopharma sell any businesses in 2026?
- Yes. In late March 2026 it sold its 22.08% stake in GC WellBeing to parent GC Corp for about 50.5 billion won, and in May 2026 it sold US vaccine subsidiary Curevo to Eli Lilly for a total deal value of $303.92 million.
Timeline
- 2026-07-24Filed for Phase 2 trial of domestic mRNA COVID-19 vaccine under Korea CDC program
- 2026-07-21IBK guidance: 2026 revenue 2.035T won (+0.6%), op. profit 75.3B won (+9.0%)
- 2026-07-02Began multinational Phase 3 trials for two-dose varicella vaccine, targeting 2028 approval
- 2026-06-22Rival SK Biopharmaceuticals signs $2.5B AI drug-discovery deal with Insilico Medicine
- 2026-06-12Stock hits 126,400 won, down 18% from May 27 after Curevo sale news
- 2026-05-31Sold US vaccine subsidiary Curevo to Eli Lilly for $303.92 million total deal value
- 2026-05-15Selected as core partner in government-backed AI drug discovery platform, ~17.7B won funding
- 2026-04-16Q1 2026 US Alyglo sales projected to jump about 300% YoY
- 2026-04-01AI antibody co-development partnership announced with Galux/Galaxus
- 2026-03-31Agreed to sell 22.08% GC WellBeing stake to parent GC Corp for ~50.5 billion won
Revision history
25 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- GC Biopharma (2026-07-01)
- GC Biopharma Corp. Company & People
- CB Insights GC Pharma profile (2026-04-25)
- The Pharmaletter (2026-03-31)
- GC Biopharma Corp. Expected to Rebound in the Second Half (2026-07-21)
- GC Biopharma Bets on Alyglo Growth (2026-04-16)
- GC Biopharma Corp.: Why Its Stock Price Is Falling Despite the Sale of Curevo (2026-06-25)
- GC shifts Wellbeing stake to Holdings (2026-04-26)
- GC Biopharma Number of Employees 2026 (2026-06-29)
- GC Biopharma Launches ALYGLO (2024-09-09)
- GC Green Cross Files for Phase 2 Trial (2026-07-24)
- GC Biopharma Corp. Begins Full-Scale Global Clinical Trials (2026-07-02)